Business, energy, technology, markets and global industry news from Business News Today

CDMO

PharmaDeviceNews CDMO
Representative image of a modern biologics manufacturing facility. Aurobindo Pharma’s TheraNym Biologics launch highlights India’s push into high-capacity CDMO infrastructure, advanced bioreactor manufacturing, and global biologics outsourcing.
Pharma & Biotech

Aurobindo Pharma launches TheraNym as MSD anchor deal strengthens biologics CDMO push

Find out how Aurobindo Pharma’s TheraNym launch could reshape India’s biologics CDMO ambitions and investor sentiment.

Read More
Representative image of radioligand therapy research for cancer-associated bone disease, highlighting how LIFT and NorthStar’s Lu-177-LT17 collaboration could advance targeted oncology treatment for bone lesions.
Pharma & Biotech

Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?

Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!

Read More
Representative image: A sterile pharmaceutical manufacturing suite with isolator-based closed processing equipment, illustrating how Curia’s Valladolid aseptic API upgrade could strengthen contamination control, Annex 1 readiness and CDMO sterile manufacturing capacity.
Pharma & Biotech

Can Curia’s Valladolid upgrade raise the bar for sterile API manufacturing?

Find out how Curia’s $4m Valladolid aseptic suite upgrade could strengthen sterile API manufacturing and Annex 1 readiness.

Read More
Representative image: A scientist reviews sequencing-style quality control data in a modern biopharma lab, illustrating how Oxford Nanopore Technologies and Lonza aim to improve GMP mRNA testing, release workflows and advanced therapy manufacturing.
Pharma & Biotech

Can Oxford Nanopore and Lonza fix the mRNA quality control bottleneck?

Find out how Oxford Nanopore and Lonza’s GMP mRNA QC solution could simplify release testing for next-generation RNA medicines.

Read More
Pharma & Biotech

Can payload-linker manufacturing help Piramal Pharma Solutions reset CDMO momentum?

ADC demand is rising, but manufacturing remains a bottleneck. Piramal Pharma Solutions is betting Riverview can narrow that gap.

Read More
Representative image of a modern pharmaceutical manufacturing facility, highlighting how Siegfried Holding AG’s acquisition of Noramco, Extractas Biosciences and Purisys could strengthen its position in complex API production, controlled-substance manufacturing and the global CDMO supply chain.
Pharma & Biotech

Can Siegfried turn Noramco’s controlled-substance expertise into a global CDMO edge?

API security is becoming a CDMO battleground. Siegfried’s Noramco deal tests whether complex small molecules can drive the next growth phase.

Read More
Pharma & Biotech

Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot

Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.

Read More
Pharma & Biotech

Scinai Immunotherapeutics doubles CDMO revenue, but can the Recipharm deal change the bigger picture?

Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.

Read More
What the Korsch X3 installation at Morpeth signals for Piramal Pharma Solutions’ commercial manufacturing strategy

How Piramal Pharma Solutions’ Morpeth tablet press upgrade sharpens its play in potent oral solid manufacturing

Piramal Pharma Solutions has added new high-containment tablet capacity at Morpeth. Read what this could change for CDMO competition and potent drug supply.

Read More
Pharma & Biotech

LGM Pharma’s $15m U.S. manufacturing expansion signals a deeper shift away from import dependence in pharma supply chains

LGM Pharma expands U.S. CDMO capacity with a $15M investment across Texas and Colorado. Explore what this means for domestic drug manufacturing. Read more.

Read More